{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:47Z","timestamp":1791874727579,"version":"4.3.4"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470816"],"award-info":[{"award-number":["82470816"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-Sen University","doi-asserted-by":"publisher","award":["50000-12220011"],"award-info":[{"award-number":["50000-12220011"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.mcp.2025.102039","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T02:27:38Z","timestamp":1750904858000},"page":"102039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Progress in the pathogenesis and treatment of pituitary neuroendocrine tumors (PitNETs): From molecular mechanisms to emerging therapies"],"prefix":"10.1016","volume":"83","author":[{"given":"Na","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naijia","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr. Rev."},{"issue":"16","key":"10.1016\/j.mcp.2025.102039_bib2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/jama.2023.5444","article-title":"Diagnosis and management of pituitary adenomas: a review","volume":"329","author":"Tritos","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41574-023-00922-4","article-title":"Pituitary stem cells: past, present and future perspectives","volume":"20","author":"P\u00e9rez Mill\u00e1n","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib4","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa205","article-title":"Pituitary neoplasm nomenclature workshop: does adenoma stand the test of time?","volume":"5","author":"Ho","year":"2021","journal-title":"J Endocr Soc"},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3171\/2023.7.JNS23858","article-title":"Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly","volume":"140","author":"Zhang","year":"2023","journal-title":"J. Neurosurg."},{"issue":"11","key":"10.1016\/j.mcp.2025.102039_bib6","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1172\/JCI138540","article-title":"DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas","volume":"130","author":"Ben-Shlomo","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.mcp.2025.102039_bib7","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib8","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EJE-21-0162","article-title":"Endocrine tumours: Thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases","volume":"185","author":"De Herdt","year":"2021","journal-title":"Eur. J. Endocrinol."},{"issue":"10","key":"10.1016\/j.mcp.2025.102039_bib9","first-page":"1017","article-title":"Clinical pathological observation of pituitary polyhormone PIT1 spectrum neuroendocrine tumor","volume":"52","author":"Duan","year":"2023","journal-title":"Chin. J. Pathol."},{"issue":"5","key":"10.1016\/j.mcp.2025.102039_bib10","first-page":"446","article-title":"Clinical pathological observation of pituitary adenoma\/neuroendocrine tumor with eosinophilic stem cells in 5 cases","volume":"53","author":"Lei","year":"2024","journal-title":"Chin. J. Pathol."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5603\/EP.a2023.0006","article-title":"Feasibility analysis of ACTH adenoma model in USP8-\/- mice","volume":"74","author":"Li","year":"2023","journal-title":"Endokrynol. Pol."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/a-1066-4592","article-title":"Updates in the medical treatment of pituitary adenomas","volume":"52","author":"Gheorghiu","year":"2020","journal-title":"Horm. Metab. Res."},{"issue":"21","key":"10.1016\/j.mcp.2025.102039_bib13","article-title":"The integrated stress response is tumorigenic and constitutes a therapeutic liability in Somatotroph adenomas","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7\u20138","key":"10.1016\/j.mcp.2025.102039_bib14","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000503791","article-title":"Cytoskeleton protein filamin A is required for efficient somatostatin receptor type 2 internalization and recycling through Rab5 and Rab4 sorting endosomes in tumor somatotroph cells","volume":"110","author":"Treppiedi","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1210\/clinem\/dgab651","article-title":"Pituitary somatotroph adenoma-derived exosomes: characterization of nonhormonal actions","volume":"107","author":"Zhou","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3892\/ijmm.2020.4807","article-title":"CDKN2A (p16INK4A) affects the anti-tumor effect of CDK inhibitor in somatotroph adenomas","volume":"47","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1210\/clinem\/dgab652","article-title":"METTL3-mediated RNA m6A hypermethylation promotes tumorigenesis and GH secretion of pituitary somatotroph adenomas","volume":"107","author":"Chang","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6489","key":"10.1016\/j.mcp.2025.102039_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/science.aat5314","article-title":"The integrated stress response: from mechanism to disease","volume":"368","author":"Costa-Mattioli","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.mcp.2025.102039_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1055\/a-1274-1330","article-title":"G-protein coupled estrogen receptor expression in growth hormone secreting and non-functioning adenomas","volume":"129","author":"Ozkaya","year":"2021","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3803\/EnM.2020.875","article-title":"Associations of GNAS mutations with surgical outcomes in patients with growth hormone-secreting pituitary adenoma","volume":"36","author":"Jung","year":"2021","journal-title":"Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s42003-022-04272-1","article-title":"Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas\/somatotroph pituitary neuroendocrine tumors","volume":"5","author":"Yamato","year":"2022","journal-title":"Commun. Biol."},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3171\/2019.12.JNS192435","article-title":"Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma","volume":"134","author":"Ashton","year":"2020","journal-title":"J. Neurosurg."},{"issue":"9","key":"10.1016\/j.mcp.2025.102039_bib23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1159\/000531200","article-title":"Clinical and proteomic-based molecular characterizations of invasive and noninvasive somatotroph PitNETs","volume":"113","author":"Chen","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.mcp.2025.102039_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110570","article-title":"Plasma-derived exosomal miRNAs as potentially novel biomarkers for latent autoimmune diabetes in adults","volume":"197","author":"Fan","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000533549","article-title":"MiR-320a acts as a tumor suppressor in somatotroph pituitary neuroendocrine tumors by targeting BCAT1","volume":"114","author":"Zhao","year":"2024","journal-title":"Neuroendocrinology"},{"issue":"9","key":"10.1016\/j.mcp.2025.102039_bib26","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/jcb.30301","article-title":"Induction of endoplasmic reticulum stress markers in an acromegaly model","volume":"123","author":"Elbialy","year":"2022","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tcb.2022.07.004","article-title":"Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications","volume":"33","author":"Zheng","year":"2023","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib28","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41392-023-01570-w","article-title":"Endoplasmic reticulum stress: molecular mechanism and therapeutic targets","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s11102-020-01029-z","article-title":"Expression patterns of ER\u03b166 and its novel variant isoform ER\u03b136 in lactotroph pituitary adenomas and associations with clinicopathological characteristics","volume":"23","author":"Mahboobifard","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.mcp.2025.102039_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.684055","article-title":"Galectin-3 and estrogen receptor alpha as prognostic markers in prolactinoma: preliminary results from a pilot study","volume":"12","author":"Bima","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.mcp.2025.102039_bib31","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1159\/000539017","article-title":"Transcriptomic profiling of lactotroph pituitary neuroendocrine tumors via RNA sequencing and ingenuity pathway analysis","volume":"114","author":"Hattori","year":"2024","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib32","first-page":"55","article-title":"MicroRNAs as potential biomarkers in pituitary adenomas","volume":"7","author":"Donati","year":"2021","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.mcp.2025.102039_bib33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.mcp.2025.102039_bib34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1530\/ERC-21-0137","article-title":"Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development","volume":"28","author":"Wang","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"10.1016\/j.mcp.2025.102039_bib35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.mcp.2025.102039_bib36","article-title":"Intranasal 15d-PGJ2 inhibits the growth of rat lactotroph pituitary neuroendocrine tumors by inducing PPAR\u03b3-dependent apoptotic and autophagic cell death","volume":"17","author":"Li","year":"2023","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1530\/JOE-19-0326","article-title":"Activin-inhibitory action on lactotrophs is decreased in lactotroph hyperplasia","volume":"244","author":"Faraoni","year":"2020","journal-title":"J. Endocrinol."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib38","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0195","article-title":"The epigenetic EZH2\/H3K27me3 axis modulates lactotroph tumor cell proliferation","volume":"257","author":"Zlocowski","year":"2023","journal-title":"J. Endocrinol."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib39","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib40","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41574-023-00916-2","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"20","author":"Petersenn","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.mcp.2025.102039_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"10.1016\/j.mcp.2025.102039_bib42","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1530\/ERC-22-0168","article-title":"TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models","volume":"29","author":"Zhang","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12902-020-00619-z","article-title":"Inhibiting MAPK14 showed anti-prolactinoma effect","volume":"20","author":"Ding","year":"2020","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib44","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12902-021-00900-9","article-title":"The role of MAPK11\/12\/13\/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Endocr. Disord."},{"issue":"7","key":"10.1016\/j.mcp.2025.102039_bib45","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1210\/clinem\/dgad020","article-title":"PRL-R variants are not only associated with prolactinomas but also with dopamine agonist resistance","volume":"108","author":"Castro Moreira","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"18","key":"10.1016\/j.mcp.2025.102039_bib46","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.7150\/ijms.51176","article-title":"Estrogen receptor \u03b1\/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas","volume":"17","author":"Xiao","year":"2020","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40618-024-02408-0","article-title":"Bromocriptine sensitivity in bromocriptine-induced drug-resistant prolactinomas is restored by inhibiting FGF19\/FGFR4\/PRL","volume":"48","author":"Zhu","year":"2025","journal-title":"J. Endocrinol. Investig."},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib48","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/neuonc\/noae241","article-title":"TRIM21-mediated ubiquitination and phosphorylation of ERK1\/2 promotes cell proliferation and drug resistance in pituitary adenomas","volume":"27","author":"Liu","year":"2025","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.mcp.2025.102039_bib49","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40618-023-02010-w","article-title":"CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma","volume":"46","author":"Wu","year":"2023","journal-title":"J. Endocrinol. Investig."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/ijmm.2020.4784","article-title":"Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5\/cyclin D1 and STAT5\/Bcl-xL signaling pathways","volume":"47","author":"Xiao","year":"2021","journal-title":"Int. J. Mol. Med."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/ERC-21-0215","article-title":"ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways","volume":"29","author":"Zhu","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mcp.2025.102039_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601984","article-title":"Regulation of the EGFR pathway by HSP90 is involved in the pathogenesis of cushing's disease","volume":"11","author":"Shen","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.mcp.2025.102039_bib53","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-18-3486","article-title":"Targeting PD-L1 initiates effective antitumor immunity in a murine model of cushing disease","volume":"26","author":"Kemeny","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.mcp.2025.102039_bib54","doi-asserted-by":"crossref","first-page":"e3346","DOI":"10.1210\/clinem\/dgab387","article-title":"Two distinctive POMC promoters modify gene expression in cushing disease","volume":"106","author":"Araki","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.mcp.2025.102039_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab178","article-title":"O-GlcNAcylation is essential for rapid pomc expression and cell proliferation in corticotropic tumor cells","volume":"162","author":"Massman","year":"2021","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.mcp.2025.102039_bib56","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac086","article-title":"Aberrant nuclear translocation of E2F1 and its association in Cushing's disease","volume":"163","author":"Araki","year":"2022","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.mcp.2025.102039_bib57","doi-asserted-by":"crossref","first-page":"e3699","DOI":"10.1210\/clinem\/dgac342","article-title":"Obesity and hyperphagia with increased defective ACTH: a novel POMC variant","volume":"107","author":"van der Valk","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib58","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/ERC-19-0448","article-title":"Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells","volume":"27","author":"Lines","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib59","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","article-title":"Targeting corticotroph HDAC and PI3-Kinase in cushing disease","volume":"106","author":"Zhang","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.mcp.2025.102039_bib60","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab167","article-title":"Effect of 3 NR3C1 mutations in the pathogenesis of pituitary ACTH adenoma","volume":"162","author":"Miao","year":"2021","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib61","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000529710","article-title":"Silibinin, an HSP90 inhibitor, on human ACTH-secreting adenomas","volume":"113","author":"Pecori Giraldi","year":"2023","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.mcp.2025.102039_bib62","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3390\/ijms23052867","article-title":"Difference in miRNA expression in functioning and silent corticotroph pituitary Adenomas indicates the role of miRNA in the regulation of corticosteroid receptors","volume":"23","author":"Mossakowska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.mcp.2025.102039_bib63","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/neuonc\/noaa084","article-title":"BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma","volume":"22","author":"Shi","year":"2020","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib64","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.18632\/aging.102751","article-title":"Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma","volume":"12","author":"Cheng","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.mcp.2025.102039_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102324","article-title":"Newly identified tumor suppressor functions of ING proteins","volume":"68","author":"Heliez","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib66","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/imm.13520","article-title":"Human FOXP3 and tumour microenvironment","volume":"168","author":"Wang","year":"2023","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib67","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.humimm.2020.03.007","article-title":"Overrepresentation of highly functional T regulatory cells in patients with nonfunctioning pituitary adenoma","volume":"81","author":"Han","year":"2020","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11033-023-09186-7","article-title":"Erythropoietin-producing hepatocellular receptor B6 is highly expressed in non-functioning pituitary neuroendocrine tumors and its expression correlates with tumor size","volume":"51","author":"Rubinfeld","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"11","key":"10.1016\/j.mcp.2025.102039_bib69","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/neuonc\/noae130","article-title":"Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting G\u03b1q\/PLC\/PKC\u03b3\/STAT3 axis","volume":"26","author":"Lin","year":"2024","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib70","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3892\/ol.2021.12525","article-title":"Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence","volume":"21","author":"Guo","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mcp.2025.102039_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.566761","article-title":"SDF-1\u03b1\/MicroRNA-134 axis regulates nonfunctioning pituitary neuroendocrine tumor growth via targeting VEGFA","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12957-021-02383-3","article-title":"Potential biomarkers of miRNA in non-functional pituitary adenomas","volume":"19","author":"Zhang","year":"2021","journal-title":"World J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib73","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3171\/2019.10.JNS191959","article-title":"MEG3\/MIR-376B-3P\/HMGA2 axis is involved in pituitary tumor invasiveness","volume":"134","author":"Zhu","year":"2020","journal-title":"J. Neurosurg."},{"issue":"11","key":"10.1016\/j.mcp.2025.102039_bib74","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41388-022-02186-0","article-title":"CircVPS13C promotes pituitary adenoma growth by decreasing the stability of IFITM1 mRNA via interacting with RRBP1","volume":"41","author":"Zhang","year":"2022","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.mcp.2025.102039_bib75","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa101","article-title":"TBR-760, a dopamine-somatostatin compound, arrests growth of aggressive nonfunctioning pituitary adenomas in mice","volume":"161","author":"Halem","year":"2020","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib76","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-19-2154","article-title":"A somatostatin receptor Subtype-3 (SST3) peptide agonist shows antitumor effects in experimental models of nonfunctioning pituitary tumors","volume":"26","author":"V\u00e1zquez-Borrego","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.mcp.2025.102039_bib77","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/ijms25073606","article-title":"The novel SSTR3 agonist ITF2984 exerts antimitotic and proapoptotic effects in human non-functioning pituitary neuroendocrine tumor (NF-PitNET) cells","volume":"25","author":"Di Muro","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib78","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12022-019-09598-x","article-title":"A novel expression profile of cell cycle and DNA repair proteins in nonfunctioning pituitary adenomas","volume":"31","author":"Metin-Armagan","year":"2020","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.mcp.2025.102039_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.598887","article-title":"Alterations in CD8+ tregs, CD56+ natural killer cells and IL-10 are associated with invasiveness of nonfunctioning pituitary adenomas (NFPAs)","volume":"27","author":"Huang","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.mcp.2025.102039_bib80","article-title":"Metabolic characteristics and M2 macrophage infiltrates in invasive nonfunctioning pituitary adenomas","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib81","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s40478-022-01441-5","article-title":"Phosphorylation of \u03b2-catenin at Serine552 correlates with invasion and recurrence of non-functioning pituitary neuroendocrine tumours","volume":"10","author":"Rai","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"10.1016\/j.mcp.2025.102039_bib82","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1007\/s11033-023-08523-0","article-title":"Differential expression levels of \u03b2-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET)","volume":"50","author":"Taghavi","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","article-title":"Multiple endocrine neoplasia type 1: latest insights","volume":"42","author":"Brandi","year":"2021","journal-title":"Endocr. Rev."},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib84","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40618-022-01873-9","article-title":"Predictors of postoperative biochemical remission in lower knosp grade growth hormone-secreting pituitary adenomas: a large single center study","volume":"46","author":"Zhang","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.mcp.2025.102039_bib85","series-title":"Endotext","article-title":"Thyrotropin-secreting pituitary adenomas","author":"Beck-Peccoz","year":"2022"},{"issue":"7","key":"10.1016\/j.mcp.2025.102039_bib86","first-page":"1677","article-title":"Pituitary adenoma following radiotherapy in childhood cancer survivors: a report from the childhood cancer survivor study","volume":"127","author":"Little","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11102-025-01522-3","article-title":"Epigenetic implications in the pathogenesis of corticotroph tumors","volume":"28","author":"Paes","year":"2025","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.mcp.2025.102039_bib88","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10735-025-10436-0","article-title":"miR-29a-3p compositely regulates the COL6A6\/PTEN-PI3K\/Akt\/CUX1 feedback loop to participate in the proliferation and invasion of pituitary adenomas","volume":"56","author":"Liu","year":"2025","journal-title":"J. Mol. Histol."},{"issue":"9","key":"10.1016\/j.mcp.2025.102039_bib89","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.3390\/ijms26094408","article-title":"MicroRNA is downregulated in invasive non-functioning pituitary adenomas","volume":"26","author":"Derwich-Rudowicz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib90","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13492","article-title":"DNA hypomethylation-related expression of hsa-miR-184 contributes to invasive growth of gonadotroph neuroendocrine pituitary tumors","volume":"37","author":"Tsegaye","year":"2025","journal-title":"J. Neuroendocrinol."},{"issue":"5","key":"10.1016\/j.mcp.2025.102039_bib91","doi-asserted-by":"crossref","first-page":"933","DOI":"10.32604\/or.2023.042581","article-title":"miR-200b-3p accelerates progression of pituitary adenomas by negatively regulating expression of RECK","volume":"32","author":"Wang","year":"2024","journal-title":"Oncol. Res."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000533549","article-title":"MiR-320a acts as a tumor suppressor in Somatotroph pituitary neuroendocrine tumors by targeting BCAT1","volume":"114","author":"Zhao","year":"2024","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib93","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/JME-21-0070","article-title":"Downregulation of miR-216a-5p and miR-652-3p is associated with growth and invasion by targeting JAK2 and PRRX1 in GH-producing pituitary tumours","volume":"68","author":"Lee","year":"2021","journal-title":"J. Mol. Endocrinol."},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23734","article-title":"Curcumin affects autophagy of prolactinoma cells by upregulating miR-206 to exert antitumor effects","volume":"38","author":"Duan","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib95","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s40618-022-01964-7","article-title":"MicroRNA-137 inhibits pituitary prolactinoma proliferation by targeting AKT2","volume":"46","author":"Xu","year":"2023","journal-title":"J. Endocrinol. Investig."},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib96","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3892\/mmr.2021.12071","article-title":"MicroRNA-29-3p regulates the \u03b2-catenin pathway by targeting IGF1 to inhibit the proliferation of prolactinoma cells","volume":"23","author":"Xia","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib97","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa220","article-title":"MicroRNA-7a2 regulates Prolactin in developing lactotrophs and prolactinoma cells","volume":"162","author":"LaPierre","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.mcp.2025.102039_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111033","article-title":"The long noncoding RNA-H19\/miRNA-93a\/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists","volume":"518","author":"Wu","year":"2020","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.mcp.2025.102039_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1268644","article-title":"CircDDX17 inhibits invasive progression of pituitary adenomas by sponging miR-1279 and regulating CADM2 expression","volume":"13","author":"Yue","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib100","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s11596-022-2676-3","article-title":"MicroRNA-149 regulates proliferation, migration, and invasion of pituitary adenoma cells by targeting ADAM12 and MMP14","volume":"42","author":"Zhang","year":"2022","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.mcp.2025.102039_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153884","article-title":"Long non-coding RNA LINC01004 promotes malignant behaviors of pituitary adenoma via miR-323a-3p\/136-5p\/RCN2 axis","volume":"234","author":"Qiu","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"7","key":"10.1016\/j.mcp.2025.102039_bib102","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/CAD.0000000000001309","article-title":"LncRNA BBOX1-AS1 promotes pituitary adenoma progression via sponging miR-361-3p\/E2F1 axis","volume":"33","author":"Wu","year":"2022","journal-title":"Anti Cancer Drugs"},{"issue":"12","key":"10.1016\/j.mcp.2025.102039_bib103","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.21037\/gs-21-720","article-title":"MicroRNA-30d target TIMP3 induces pituitary tumor cell growth and invasion","volume":"10","author":"Sun","year":"2021","journal-title":"Gland Surg."},{"key":"10.1016\/j.mcp.2025.102039_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111350","article-title":"LINC01116 boosts the progression of pituitary adenoma via regulating miR-744-5p\/HOXB8 pathway","volume":"536","author":"Huang","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib105","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41419-021-03812-7","article-title":"Long non-coding RNA TUG1\/microRNA-187-3p\/TESC axis modulates progression of pituitary adenoma via regulating the NF-\u03baB signaling pathway","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mcp.2025.102039_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.567021","article-title":"JAG1, regulated by microRNA-424-3p, involved in tumorigenesis and epithelial-mesenchymal transition of high proliferative potential-pituitary adenomas","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.mcp.2025.102039_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111083","article-title":"Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas","volume":"520","author":"Wei","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11011-020-00611-5","article-title":"LncRNA SNHG7 sponges miR-449a to promote pituitary adenomas progression","volume":"36","author":"Yue","year":"2021","journal-title":"Metab. Brain Dis."},{"issue":"12","key":"10.1016\/j.mcp.2025.102039_bib109","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/ijc.33268","article-title":"miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance","volume":"147","author":"Bogner","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1139\/bcb-2019-0336","article-title":"MiR-448 targets BLC2 and inhibits the growth of pituitary adenoma cells","volume":"98","author":"He","year":"2020","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.mcp.2025.102039_bib111","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fendo.2020.00092","article-title":"MiR-130a-3p inhibits PRL expression and is associated with heat stress-induced PRL reduction","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.mcp.2025.102039_bib112","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/09168451.2020.1715780","article-title":"MiR-219a-2-3p suppresses cell proliferation and promotes apoptosis by targeting MDM2\/p53 in pituitary adenomas cells","volume":"84","author":"Wang","year":"2020","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib113","first-page":"21","article-title":"MicroRNA-146b-5p\/EPHA7 axis regulates cell invasion, metastasis, proliferation, and temozolomide-induced chemoresistance via regulation of IRAK4\/TRAF6\/NF-\u03baB signaling pathway in aggressive pituitary adenoma","volume":"37","author":"Lou","year":"2022","journal-title":"Histol. Histopathol."},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib114","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41419-021-03861-y","article-title":"LncRNA LINC00473 is involved in the progression of invasive pituitary adenoma by upregulating KMT5A via ceRNA-mediated miR-502-3p evasion","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"issue":"10","key":"10.1016\/j.mcp.2025.102039_bib115","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.18632\/aging.203048","article-title":"LncRNA MEG8 promotes TNF-\u03b1 expression by sponging miR-454-3p in bone-invasive pituitary adenomas","volume":"13","author":"Zhu","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib116","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10565-020-09570-0","article-title":"Up-regulation of the expressions of MiR-149-5p and MiR-99a-3p in exosome inhibits the progress of pituitary adenomas","volume":"37","author":"Zhao","year":"2021","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.mcp.2025.102039_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111140","article-title":"CircNFIX promotes progression of pituitary adenoma via CCNB1 by sponging miR-34a -5p","volume":"525","author":"Cheng","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"issue":"5","key":"10.1016\/j.mcp.2025.102039_bib118","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41574-024-00953-5","article-title":"The shift of therapeutic strategy for prolactinomas: surgery as the first-line option","volume":"20","author":"Wu","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"10.1016\/j.mcp.2025.102039_bib119","first-page":"5113","article-title":"Diagnosis and treatment of acromegaly: an endocrine society clinical practice guideline","volume":"104","author":"Melmed","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.mcp.2025.102039_bib120","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1210\/jc.2008-0125","article-title":"The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"93","author":"Nieman","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib121","first-page":"114","article-title":"Medical treatment of prolactinomas","volume":"19","author":"Molitch","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.mcp.2025.102039_bib122","article-title":"Management of pituitary tumours","volume":"342","author":"Wass","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.mcp.2025.102039_bib123","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001532","article-title":"Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study","volume":"8","author":"Majd","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.mcp.2025.102039_bib125","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1210\/clinem\/dgaa805","article-title":"EGFR\/ErbB2-Targeting lapatinib therapy for aggressive prolactinomas","volume":"106","author":"Cooper","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.mcp.2025.102039_bib126","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mcp.2025.102039_bib127","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.wneu.2018.12.174","article-title":"Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review","volume":"124","author":"Wang","year":"2019","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.47391\/JPMA.22-005","article-title":"Stereotactic radiosurgery for pituitary adenomas: a review of literature","volume":"72","author":"Siddiqui","year":"2022","journal-title":"J. Pakistan Med. Assoc."},{"issue":"1","key":"10.1016\/j.mcp.2025.102039_bib129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clon.2016.09.012","article-title":"Time dependence of radiation-induced hypothalamic-pituitary axis dysfunction in adults treated for non-pituitary, intracranial neoplasms","volume":"29","author":"Taku","year":"2017","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.mcp.2025.102039_bib130","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1456922","article-title":"Everolimus in pituitary tumor: a review of preclinical and clinical evidence","volume":"15","author":"Yao","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.mcp.2025.102039_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.608422","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas","volume":"11","author":"Dai","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"17","key":"10.1016\/j.mcp.2025.102039_bib132","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.3390\/cancers14174093","article-title":"Immunotherapy for aggressive and metastatic pituitary neuroendocrine tumors (PitNETs): State-of-the art","volume":"14","author":"Feola","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850825000325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850825000325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T03:48:43Z","timestamp":1762314523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850825000325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":132,"alternative-id":["S0890850825000325"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2025.102039","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in the pathogenesis and treatment of pituitary neuroendocrine tumors (PitNETs): From molecular mechanisms to emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2025.102039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102039"}}